A retrospective study (n = 205) found that high PD-L1 expression (≥50%) was associated with shorter first-line time to treatment failure (TTF) in patients with advanced NSCLC harboring BRAF V600 mutation, regardless of targeted therapy (BRAF inhibitor/MEK inhibitor) or immunotherapy, underscoring the distinct immune microenvironment biology of this molecular subset (33). This evidence concerns the gene BRAF and non-small cell lung carcinoma.